

Arif Ali Awan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6488151/publications.pdf>

Version: 2024-02-01

23
papers

171
citations

1651377

6
h-index

1336881

12
g-index

23
all docs

23
docs citations

23
times ranked

114
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. Supportive Care in Cancer, 2022, 30, 3977-3984.	1.0	5
2	Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial). Cancer Research, 2022, 82, OT1-01-01-OT1-01-01.	0.4	1
3	Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).. Journal of Clinical Oncology, 2022, 40, 605-605.	0.8	0
4	Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors. JAMA Network Open, 2022, 5, e2219128.	2.8	4
5	Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Supportive Care in Cancer, 2021, 29, 925-943.	1.0	28
6	A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management. Breast Cancer Research and Treatment, 2021, 185, 533-547.	1.1	4
7	Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey. Journal of Bone Oncology, 2021, 26, 100339.	1.0	10
8	Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. Journal of Bone Oncology, 2021, 26, 100343.	1.0	6
9	Abstract PS9-47: A scoping review characterizing "choosing wisely" recommendations for breast cancer management. , 2021, , .		0
10	A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. Supportive Care in Cancer, 2021, 29, 5787-5795.	1.0	6
11	Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey. Breast Cancer Research and Treatment, 2021, 187, 477-486.	1.1	6
12	Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. Journal of Bone Oncology, 2021, 27, 100351.	1.0	4
13	Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. Supportive Care in Cancer, 2021, 29, 6903-6912.	1.0	6
14	The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience. Frontiers in Oncology, 2021, 11, 687730.	1.3	9
15	A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Breast, 2021, 58, 42-49.	0.9	4
16	A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. Current Oncology, 2021, 28, 5073-5083.	0.9	5
17	A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer. Supportive Care in Cancer, 2020, 28, 4891-4899.	1.0	17
18	Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.. Journal of Clinical Oncology, 2020, 38, e24083-e24083.	0.8	1

#	ARTICLE	IF	CITATIONS
19	A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. Breast Cancer Research and Treatment, 2019, 178, 337-345.	1.1	7
20	Optimal frequency of scans for patients on cancer therapies: A population kinetics assessment. Cancer Medicine, 2019, 8, 6871-6886.	1.3	5
21	Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). Breast Cancer Research and Treatment, 2019, 177, 93-101.	1.1	15
22	De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2019, 176, 507-517.	1.1	23
23	De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?. Journal of Oncology Practice, 2018, 14, 465-467.	2.5	5